MPA approval in China of Sylvant for Idiopathic Multicentric Castleman Disease. BeiGene + EUSA Pharma
This disease is a rare, life-threatening, and debilitating condition of the lymph nodes and related tissues.
Siltuximab is a monoclonal antibody approved in the United States, European Union, and other countries and regions around the world.
The approval of siltuximab for the treatment of iMCD was supported by clinical results from a multinational, randomized, double blind, placebo-controlled Phase II trial (NCT01024036) conducted in 79 patients from 19 countries and regions, including 16 patients from China.
Related news and insights
argenx a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Vyvgart (efgartigimod alfa-fcab) as an add-on to standard therapy for the treatment of adult patients with gMG who are AChR antibody positive.
Telix Pharmaceuticals announces that the FDA has approved a supplementary New Drug Application (sNDA) for Illuccix (kit for the preparation of gallium Ga 68 gozetotide injection) to enable its use for the selection of patients with metastatic prostate cancer, for whom 177Lu 177 PSMA-directed therapy is indicated.
Regeneron Pharmaceuticals, Inc.and Sanofi announced that the European Commission (EC) has approved Dupixent (dupilumab) in the European Union (EU) to treat severe atopic dermatitis in children aged 6 months to 5 years old who are candidates for systemic therapy . With this approval, Dupixent is the first and only targeted medicine indicated to treat these young children in Europe and the U.S.